menu
    • menu
    [{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AIO-Studien-gGmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Maruho","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Human Drug Research \/ Maruho"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Maruho","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Maruho"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Eastern Virginia Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Eastern Virginia Medical School","highestDevelopmentStatusID":"10","companyTruncated":"Inova Health Care Services \/ Eastern Virginia Medical School"},{"orgOrder":0,"company":"Ectycell","sponsor":"Pierre and Marie Curie University | INSERM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ectycell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ectycell \/ Pierre and Marie Curie University | INSERM","highestDevelopmentStatusID":"6","companyTruncated":"Ectycell \/ Pierre and Marie Curie University | INSERM"}]

    Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_2991

    Menu

    DSSTox_CID_2991

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inova Health Care Services

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Inova Health Care Services

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Eastern Virginia Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

                            Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fetal Membranes, Premature Rupture.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 23, 2024

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Eastern Virginia Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Lifesciences

                            India arrow
                            AllPack Indonesia
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Receives Final Approval from The USFDA for Erythromycin Tablets USP, 250 mg and 500 mg

                            Details : Erythromycin acts by inhibition of protein synthesis by binding to the 23S ribosomal RNA molecule in the 50S subunit of ribosomes in susceptible bacterial organisms.

                            Product Name : Erythromycin

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 09, 2023

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centre for Human Drug Research

                            Netherlands arrow
                            AllPack Indonesia
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Maruho

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

                            Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 20, 2019

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Maruho

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centre for Human Drug Research

                            Netherlands arrow
                            AllPack Indonesia
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Maruho

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intradermal LPS and Antibiotics

                            Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammatory Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 19, 2018

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Maruho

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AIO-Studien-gGmbH

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            AIO-Studien-gGmbH

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL ...

                            Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 20, 2012

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ectycell

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Ectycell

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Pierre and Marie Curie University | INSERM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement o...

                            Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 19, 2011

                            Lead Product(s) : Erythromycin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Pierre and Marie Curie University | INSERM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth